Industry gets first view of FDA reform legislation
This article was originally published in Clinica
Executive Summary
The US medical device industry gave a less than warm reception to the latest House FDA reform legislation as representatives took their first look last week. Their initial reaction: Nancy Kassebaum's senate bill is better. For one thing, the Kansas Republican specifies a 180-day review clock; the House version does not, reports Clinica's Washington correspondent, Duffy Miller.